{"id":"NCT01403116","sponsor":"Clarus Therapeutics, Inc.","briefTitle":"Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","officialTitle":"Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2011-07-27","resultsPosted":"2018-08-14","lastUpdate":"2018-08-14"},"enrollment":325,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Male Hypogonadism"],"interventions":[{"type":"DRUG","name":"Oral testosterone undecanoate","otherNames":["Oral TU"]},{"type":"DRUG","name":"topical testosterone gel","otherNames":["T-gel"]}],"arms":[{"label":"Oral testosterone undecanoate (TU)","type":"EXPERIMENTAL"},{"label":"topical testosterone gel","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.","primaryOutcome":{"measure":"Percentage of Treated Patients With Average Serum Testosterone (T) Concentrations (Cavg) Between 300 and 1000 ng/dL","timeFrame":"Following 90 days of treatment","effectByArm":[{"arm":"Oral Testosterone Undecanoate (TU)","deltaMin":83.6,"sd":null},{"arm":"Topical Testosterone Gel","deltaMin":79.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":16},"locations":{"siteCount":30,"countries":["United States","Germany"]},"refs":{"pmids":["36272969"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":161},"commonTop":["Polycythaemia","Nasopharyngitis","Hypertension","Upper respiratory tract infection","Prostatomegaly"]}}